Antiparasitic Drugs Market Analysis

Antiparasitic Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on drug type, the global antiparasitic drugs is segmented into anthelmintics, antiprotozoal, ectoparasiticides, and other drug types. The anthelminthics segment held the largest market share of 50.2% in 2023.
 

• Helminthic infections, caused by parasitic worms, are widespread in many parts of the world, especially in tropical and subtropical regions.
   
• For instance, according to the Pan American Health Organization, approximately 1.5 billion people are infected with soil-transmitted helminths worldwide, making this the most common infection in the world. Also, as per Centers for Disease Control and Prevention, ~ 807 to 1,121 million people are infected with Ascaris globally.
   
• Anthelmintics drugs are designed to target various types of helminths, including nematodes (roundworms), cestodes (tapeworms), and trematodes (flukes). This broad spectrum of activity makes anthelmintics versatile in treating different parasitic worm infections and thereby fosters the segmental growth.
   

Based on route of administration, the global antiparasitic drugs is classified into injectable, oral, and topical. The injectable segment held the largest market revenue of USD 11.7 billion in 2023.
 

• Injectable formulations often provide a faster onset of action compared to oral formulations. Additionally, some antiparasitic drugs have better bioavailability when administered through the injectable route, ensuring that a higher proportion of the drug reaches the systemic circulation.
   
• Further, injectable formulations are widely used in clinical trials and research studies to evaluate the safety and efficacy of new antiparasitic drugs. This contributes to the high use of injectable antiparasitic drugs, thereby contributing towards high segmental growth.
   

Based on End user, the global antiparasitic drugs is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to reach the largest market revenue of USD 14.7 billion by 2032.
 

• Hospital pharmacies maintain a diverse range of antiparasitic medications, ensuring comprehensive treatment options for various parasitic infections. Additionally, hospitals serve as the primary point of care for patients with severe or complicated parasitic conditions, further leading to increased patient footfall in these pharmacies.
   
• Moreover, these pharmacies along with their skilled staffs provide a controlled environment and center for the administration of drugs, ensuring accurate dosing, monitoring, and management of potential side effects. All these factors together boost the segmental growth.
   

In 2023, North America held a significant share of 36.8% in the global antiparasitic drugs market.
 

• High market growth can be attributed to increasing cases of parasitic infections in the region. For instance, according to the World Health Organization, in 2021, more than 723,000 cases of malaria were reported in North America. Furthermore, as per the report published by the Sepsis Organization, in 2021, toxoplasmosis and giardia infections are the two most common parasitic infections in North America.
   
• Further, North America, particularly the U.S., has one of the highest levels of healthcare spending globally. This substantial investment in healthcare infrastructure and services contributes to the prominence of the region in various pharmaceutical markets, including antiparasitic drugs.
   

Such aforementioned factors are expected to propel the antiparasitic drugs in the North American market.